$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000142545019000042 Filed on May 09, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q4
Revenue	$18.20M	$14.66M	$14.57M
YoY Change	20.71%	21.18%	24.72%
Cost Of Revenue	$4.581M	$4.001M	$4.050M
YoY Change	20.33%	26.02%	-54.14%
Gross Profit	$13.62M	$10.66M	$10.51M
YoY Change	20.84%	19.46%	19.04%
Gross Profit Margin	74.83%	72.7%	72.17%
Selling, General & Admin	$14.18M	$12.16M	$11.10M
YoY Change	15.48%	0.52%	-8.26%
% of Gross Profit	104.08%	114.12%	105.57%
Research & Development	$1.234M	$1.213M	$1.280M
YoY Change	10.67%	-0.41%	36.17%
% of Gross Profit	9.06%	11.38%	12.17%
Depreciation & Amortization	$1.080M	$828.0K	$710.0K
YoY Change	50.0%	21.59%	7.58%
% of Gross Profit	7.93%	7.77%	6.75%
Operating Expenses	$15.41M	$13.37M	$12.38M
YoY Change	15.08%	0.44%	-5.06%
Operating Profit	-$1.790M	-$2.717M	-$1.866M
YoY Change	-15.57%	-38.18%	-55.61%
Interest Expense	-$630.0K	-$300.0K	-$530.0K
YoY Change	12.5%	-45.45%	-15.87%
% of Operating Profit
Other Income/Expense, Net	-$669.0K	-$303.0K	-$70.00K
YoY Change	16.96%	-49.92%	600.0%
Pretax Income	-$2.459M	-$3.020M	-$2.470M
YoY Change	-8.59%	-39.6%	-49.07%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.618M	-$3.020M	-$2.468M
YoY Change	-2.75%	-39.6%	-49.06%
Net Earnings / Revenue	-14.38%	-20.61%	-16.94%
Basic Earnings Per Share
Diluted Earnings Per Share	-$181.3K	-$210.2K	-$189.7K
COMMON SHARES
Basic Shares Outstanding	14.68M shares	14.54M shares	12.81M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.90M	$52.80M	$60.70M
YoY Change	-17.36%	52.6%	42.49%
Cash & Equivalents	$21.86M	$52.77M	$60.69M
Short-Term Investments
Other Short-Term Assets	$36.70M	$1.500M	$1.300M
YoY Change	3236.36%	36.36%	62.5%
Inventory	$32.86M	$28.08M	$25.71M
Prepaid Expenses
Receivables	$14.97M	$10.30M	$8.999M
Other Receivables	$500.0K	$500.0K	$500.0K
Total Short-Term Assets	$106.8M	$93.11M	$97.16M
YoY Change	70.31%	41.19%	39.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.92M	$16.79M	$12.77M
YoY Change	63.78%	36.72%	22.88%
Goodwill	$10.97M		$0.00
YoY Change
Intangibles		$2.106M	$2.181M
YoY Change		-12.76%	-7.15%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$23.67M	$18.90M	$2.181M
YoY Change	56.68%	28.59%	-82.88%
TOTAL ASSETS
Total Short-Term Assets	$106.8M	$93.11M	$97.16M
Total Long-Term Assets	$23.67M	$18.90M	$2.181M
Total Assets	$151.4M	$112.0M	$112.1M
YoY Change	94.53%	38.89%	36.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.000M	$6.344M	$3.971M
YoY Change	9.99%	-11.85%	-27.73%
Accrued Expenses	$4.000M	$2.700M	$3.600M
YoY Change	25.0%	17.39%	24.14%
Deferred Revenue
YoY Change
Short-Term Debt	$30.00M	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.12M	$120.0K	$118.0K
YoY Change	26092.17%	5.26%	4.42%
Total Short-Term Liabilities	$42.19M	$10.82M	$9.217M
YoY Change	302.16%	2.39%	-2.64%
LONG-TERM LIABILITIES
Long-Term Debt	$21.11M	$21.13M	$21.16M
YoY Change	-16.55%	-16.53%	-16.51%
Other Long-Term Liabilities	$100.0K		$0.00
YoY Change
Total Long-Term Liabilities	$21.16M	$21.13M	$21.16M
YoY Change	-16.35%	-16.53%	-16.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.19M	$10.82M	$9.217M
Total Long-Term Liabilities	$21.16M	$21.13M	$21.16M
Total Liabilities	$63.35M	$31.96M	$30.37M
YoY Change	77.01%	-10.96%	-12.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$120.7M	-$118.1M	-$115.1M
YoY Change	9.0%	9.3%	0.0%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	100.0%	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$88.08M	$80.05M	$81.73M
YoY Change
Total Liabilities & Shareholders Equity	$151.4M	$112.0M	$112.1M
YoY Change	94.53%	38.89%	36.21%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q4
OPERATING ACTIVITIES
Net Income	-$2.618M	-$3.020M	-$2.468M
YoY Change	-2.75%	-39.6%	-49.06%
Depreciation, Depletion And Amortization	$1.080M	$828.0K	$710.0K
YoY Change	50.0%	21.59%	7.58%
Cash From Operating Activities	-$6.940M	-$3.471M	-$2.720M
YoY Change	4.52%	-31.04%	-18.32%
INVESTING ACTIVITIES
Capital Expenditures	-$3.700M	$4.963M	$50.00K
YoY Change	160.56%	79.11%	-104.0%
Acquisitions		$0.00
YoY Change
Other Investing Activities	-$49.97M		-$500.0K
YoY Change
Cash From Investing Activities	-$53.68M	-$4.982M	-$460.0K
YoY Change	3680.28%	70.03%	-63.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net		$29.00K
YoY Change		3.57%
Cash From Financing Activities	30.06M	$536.0K	39.42M
YoY Change	-100300.0%	-2014.29%	-12.24%
NET CHANGE
Cash From Operating Activities	-6.940M	-$3.471M	-2.720M
Cash From Investing Activities	-53.68M	-$4.982M	-460.0K
Cash From Financing Activities	30.06M	$536.0K	39.42M
Net Change In Cash	-30.56M	-$7.917M	36.24M
YoY Change	277.75%	-0.93%	-10.16%
FREE CASH FLOW
Cash From Operating Activities	-$6.940M	-$3.471M	-$2.720M
Capital Expenditures	-$3.700M	$4.963M	$50.00K
Free Cash Flow	-$3.240M	-$8.434M	-$2.770M
YoY Change	-37.93%	8.07%	33.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	ORTHOPEDIATRICS CORP
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14678027	shares
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134000	USD
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14682398	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14682398	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14538202	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14682398	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14682398	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14538202	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14538202	shares
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q1	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52774000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10296000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8999000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	28081000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	25708000	USD
CY2019Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	508000	USD
CY2018Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	502000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1452000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1256000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	93111000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	97156000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16789000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12768000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1846000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1921000	USD
CY2019Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	260000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	260000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2106000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2181000	USD
CY2019Q1	us-gaap	Assets Assets	112006000	USD
CY2018Q4	us-gaap	Assets Assets	112105000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6344000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3971000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2670000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3552000	USD
CY2019Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	120000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	118000	USD
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1689000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1576000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10823000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9217000	USD
CY2019Q1	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21134000	USD
CY2018Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21156000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21134000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21156000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	31957000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	30373000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198478000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	197442000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118111000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115091000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-322000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-623000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	80049000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112006000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112105000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14656000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12094000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4001000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3175000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	10655000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	8919000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6547000	USD
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6079000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5612000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6017000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1213000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1218000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	13372000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	13314000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2717000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4395000	USD
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-303000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-552000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-53000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-303000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-605000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14367056	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12073776	shares
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	301000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	82000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	82000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2719000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4918000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	565000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	471000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	80049000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	47495000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	82000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2177000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	44754000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	828000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	681000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	471000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2177000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	1180000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	1235000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	196000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	283000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2373000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1702000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-719000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7917000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-600000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-128000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-82000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3471000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5033000	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19000	USD
CY2018Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	159000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4963000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2771000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4982000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2930000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	29000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	28000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	565000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	536000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7991000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42582000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52774000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34591000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	303000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	552000	USD
CY2019Q1	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	217000	USD
CY2018Q1	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	304000	USD
CY2019Q1	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard and Pediatric Nailing Platform \| Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. In September 2018, we further expanded operations in Canada selling direct to local hospitals, and in January 2019 we expanded to Belgium and the Netherlands. Additionally, in March 2019 we established a holding company and an operating company in the Netherlands that are expected to enhance our operations in Europe. </span></div>Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118111000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115091000	USD
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	335000	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y7M6D
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1213000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1218000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	2302000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	21254000	USD
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	21274000	USD
CY2019Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	120000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	118000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21134000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21156000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	87345000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	1062000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation	16200000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	9736000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	22430000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	112094	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.32
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M18D
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18427	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	30.66
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93667	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.25
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6790	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	27.81
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6790	shares
CY2019Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	27.81
CY2019Q1	kids	Classof Warrantor Right Exercised ClassofWarrantorRightExercised	0	shares
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3020000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5000000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14367056	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12073776	shares
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	403269	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	881846	shares
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q1	us-gaap	Revenues Revenues	14656000	USD
CY2018Q1	us-gaap	Revenues Revenues	12094000	USD
CY2019Q1	us-gaap	Revenues Revenues	14656000	USD
CY2018Q1	us-gaap	Revenues Revenues	12094000	USD
CY2018Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2019Q1	kids	Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment	500000	USD

Files In Submission

Name	View Source	Status
0001425450-19-000042-index-headers.html	Edgar Link	pending
0001425450-19-000042-index.html	Edgar Link	pending
0001425450-19-000042.txt	Edgar Link	pending
0001425450-19-000042-xbrl.zip	Edgar Link	pending
exhibit311-ceocertific.htm	Edgar Link	pending
exhibit312-cfocertific.htm	Edgar Link	pending
exhibit321-ceocertific.htm	Edgar Link	pending
exhibit322-cfocertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20190331.htm	Edgar Link	pending
kids-20190331.xsd	Edgar Link	pending
kids-20190331_cal.xml	Edgar Link	unprocessable
kids-20190331_def.xml	Edgar Link	unprocessable
kids-20190331_htm.xml	Edgar Link	completed
kids-20190331_lab.xml	Edgar Link	unprocessable
kids-20190331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2019 Q2 Form 10-Q Financial Statement

#000142545019000042 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2019 Q2 Form 10-Q Financial Statement

#000142545019000042 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids